Get notified when TVTX files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts
NASDAQ: TVTX Travere Therapeutics, Inc. 8-K

Travere raises $525M via convertible notes, using $351M to repurchase existing 2029 debt

Filed May 11, 2026 · Period ending May 6, 2026 · ~1 min read

Key Changes

  • high

    Completed $525M offering of 0.50% convertible senior notes due 2032, convertible at $64.90/share (15.4 shares per $1,000 note). Conversion allowed when stock trades above $84.37 for 20 of 30 days, creating potential dilution if stock rises significantly.

  • high

    Net proceeds of ~$508.5M will fund $350.9M repurchase of existing 2029 convertible notes ($221.4M principal plus accrued interest), with remainder for commercialization, R&D, and working capital. Debt refinancing extends maturity and reduces interest rate.

  • medium

    Notes cannot be redeemed before May 2029; after that, only if stock exceeds $84.37 for 20 of 30 days and at least $75M notes remain outstanding. Limits company's flexibility to retire debt early unless stock performs well.

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (PXED 10-Q) is open in full — no account needed.

Partner

Trade TVTX commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?